Adequacy of early‑stage breast cancer systemic adjuvant treatment to Saint Gallen‑2013 statement: the MCC‑Spain study

The St Gallen Conference endorsed in 2013 a series of recommendations on early breast cancer treatment. The main purpose of this article is to ascertain the clinical factors associated with St Gallen-2013 recommendations accomplishment. A cohort of 1152 breast cancer cases diagnosed with pathologica...

Descripción completa

Detalles Bibliográficos
Autores: Gómez Acebo, Inés, Dierssen Sotos, Trinidad, Mirones, Mónica, Alguacil Ojeda, Juan
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universidad de Huelva (UHU)
Repositorio:Arias Montano. Repositorio Institucional de la Universidad de Huelva
Idioma:inglés
OAI Identifier:oai:ariasmontano.uhu.es:10272/19593
Acceso en línea:http://hdl.handle.net/10272/19593
Access Level:acceso abierto
Palabra clave:Early-stage
Breast cancer
Systemic adjuvant treatment
MCC-Spain
Saint Gallen‑2013
id ES_826ba658d84eeb6e7c6f2e4ca645bfbd
oai_identifier_str oai:ariasmontano.uhu.es:10272/19593
network_acronym_str ES
network_name_str España
repository_id_str
spelling Adequacy of early‑stage breast cancer systemic adjuvant treatment to Saint Gallen‑2013 statement: the MCC‑Spain studyGómez Acebo, InésDierssen Sotos, TrinidadMirones, MónicaAlguacil Ojeda, JuanEarly-stageBreast cancerSystemic adjuvant treatmentMCC-SpainSaint Gallen‑2013The St Gallen Conference endorsed in 2013 a series of recommendations on early breast cancer treatment. The main purpose of this article is to ascertain the clinical factors associated with St Gallen-2013 recommendations accomplishment. A cohort of 1152 breast cancer cases diagnosed with pathological stage < 3 in Spain between 2008 and 2013 was begun and then followed-up until 2017/2018. Data on patient and tumour characteristics were obtained from medical records, as well as their first line treatment. First line treatments were classified in three categories, according on whether they included the main St Gallen-2013 recommendations, more than those recommended or less than those recommended. Multinomial logistic regression models were carried out to identify factors associated with this classification and Weibull regression models were used to find out the relationship between this classification and survival. About half of the patients were treated according to St Gallen recommendations; 21% were treated over what was recommended and 33% received less treatment than recommended. Factors associated with treatment over the recommendations were stage II (relative risk ratio [RRR] = 4.2, 2.9–5.9), cancer positive to either progesterone (RRR = 8.1, 4.4–14.9) or oestrogen receptors (RRR = 5.7, 3.0–11.0). Instead, factors associated with lower probability of treatment over the recommendations were age (RRR = 0.7 each 10 years, 0.6–0.8), poor differentiation (RRR = 0.09, 0.04–0.19), HER2 positive (RRR = 0.46, 0.26–0.81) and triple negative cancer (RRR = 0.03, 0.01–0.11). Patients treated less than what was recommended in St Gallen had cancers in stage 0 (RRR = 21.6, 7.2–64.5), poorly differentiated (RRR = 1.9, 1.2–2.9), HER2 positive (RRR = 3.4, 2.4–4.9) and luminal B-like subtype (RRR = 3.6, 2.6–5.1). Women over 65 years old had a higher probability of being treated less than what was recommended if they had luminal B-like, HER2 or triple negative cancer. Treatment over St Gallen was associated with younger women and less severe cancers, while treatment under St Gallen was associated with older women, more severe cancers and cancers expressing HER2 receptors.Nature Research20212021-03-0120212021-03-01journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10272/19593reponame:Arias Montano. Repositorio Institucional de la Universidad de Huelvainstname:Universidad de Huelva (UHU)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Atribución-NoComercial-SinDerivadas 3.0 Españahttp://creativecommons.org/licenses/by-nc-nd/3.0/es/info:eu-repo/semantics/openAccessoai:ariasmontano.uhu.es:10272/195932026-06-02T14:58:11Z
dc.title.none.fl_str_mv Adequacy of early‑stage breast cancer systemic adjuvant treatment to Saint Gallen‑2013 statement: the MCC‑Spain study
title Adequacy of early‑stage breast cancer systemic adjuvant treatment to Saint Gallen‑2013 statement: the MCC‑Spain study
spellingShingle Adequacy of early‑stage breast cancer systemic adjuvant treatment to Saint Gallen‑2013 statement: the MCC‑Spain study
Gómez Acebo, Inés
Early-stage
Breast cancer
Systemic adjuvant treatment
MCC-Spain
Saint Gallen‑2013
title_short Adequacy of early‑stage breast cancer systemic adjuvant treatment to Saint Gallen‑2013 statement: the MCC‑Spain study
title_full Adequacy of early‑stage breast cancer systemic adjuvant treatment to Saint Gallen‑2013 statement: the MCC‑Spain study
title_fullStr Adequacy of early‑stage breast cancer systemic adjuvant treatment to Saint Gallen‑2013 statement: the MCC‑Spain study
title_full_unstemmed Adequacy of early‑stage breast cancer systemic adjuvant treatment to Saint Gallen‑2013 statement: the MCC‑Spain study
title_sort Adequacy of early‑stage breast cancer systemic adjuvant treatment to Saint Gallen‑2013 statement: the MCC‑Spain study
dc.creator.none.fl_str_mv Gómez Acebo, Inés
Dierssen Sotos, Trinidad
Mirones, Mónica
Alguacil Ojeda, Juan
author Gómez Acebo, Inés
author_facet Gómez Acebo, Inés
Dierssen Sotos, Trinidad
Mirones, Mónica
Alguacil Ojeda, Juan
author_role author
author2 Dierssen Sotos, Trinidad
Mirones, Mónica
Alguacil Ojeda, Juan
author2_role author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Early-stage
Breast cancer
Systemic adjuvant treatment
MCC-Spain
Saint Gallen‑2013
topic Early-stage
Breast cancer
Systemic adjuvant treatment
MCC-Spain
Saint Gallen‑2013
description The St Gallen Conference endorsed in 2013 a series of recommendations on early breast cancer treatment. The main purpose of this article is to ascertain the clinical factors associated with St Gallen-2013 recommendations accomplishment. A cohort of 1152 breast cancer cases diagnosed with pathological stage < 3 in Spain between 2008 and 2013 was begun and then followed-up until 2017/2018. Data on patient and tumour characteristics were obtained from medical records, as well as their first line treatment. First line treatments were classified in three categories, according on whether they included the main St Gallen-2013 recommendations, more than those recommended or less than those recommended. Multinomial logistic regression models were carried out to identify factors associated with this classification and Weibull regression models were used to find out the relationship between this classification and survival. About half of the patients were treated according to St Gallen recommendations; 21% were treated over what was recommended and 33% received less treatment than recommended. Factors associated with treatment over the recommendations were stage II (relative risk ratio [RRR] = 4.2, 2.9–5.9), cancer positive to either progesterone (RRR = 8.1, 4.4–14.9) or oestrogen receptors (RRR = 5.7, 3.0–11.0). Instead, factors associated with lower probability of treatment over the recommendations were age (RRR = 0.7 each 10 years, 0.6–0.8), poor differentiation (RRR = 0.09, 0.04–0.19), HER2 positive (RRR = 0.46, 0.26–0.81) and triple negative cancer (RRR = 0.03, 0.01–0.11). Patients treated less than what was recommended in St Gallen had cancers in stage 0 (RRR = 21.6, 7.2–64.5), poorly differentiated (RRR = 1.9, 1.2–2.9), HER2 positive (RRR = 3.4, 2.4–4.9) and luminal B-like subtype (RRR = 3.6, 2.6–5.1). Women over 65 years old had a higher probability of being treated less than what was recommended if they had luminal B-like, HER2 or triple negative cancer. Treatment over St Gallen was associated with younger women and less severe cancers, while treatment under St Gallen was associated with older women, more severe cancers and cancers expressing HER2 receptors.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-03-01
2021
2021-03-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10272/19593
url http://hdl.handle.net/10272/19593
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución-NoComercial-SinDerivadas 3.0 España
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución-NoComercial-SinDerivadas 3.0 España
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Nature Research
publisher.none.fl_str_mv Nature Research
dc.source.none.fl_str_mv reponame:Arias Montano. Repositorio Institucional de la Universidad de Huelva
instname:Universidad de Huelva (UHU)
instname_str Universidad de Huelva (UHU)
reponame_str Arias Montano. Repositorio Institucional de la Universidad de Huelva
collection Arias Montano. Repositorio Institucional de la Universidad de Huelva
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412045447757824
score 15,811543

Similares en LA Referencia